1- (6- ethoxy- 5- (3- ethyl- 6,7- dihydro- 2- (2- methoxyethyl)- 7- oxo- 2H- pyrazolo(4,3- d)pyrimidin- 5- yl)- 3- pyridyl sulphonyl)-4-ethylpiperazine

a phosphodiesterase inhibitor; structure in first source

Also Known As:

1-(6-ethoxy-5-(3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo(4,3-d)pyrimidin-5-yl)-3-pyridyl sulphonyl)-4-ethylpiperazine benzenesulphonate; UK 369,003; UK 369003; UK-369,003; UK-369003; UK369,003; UK369003

Networked: 3 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Crossland, Anna: 2 articles (09/2010 - 09/2010)
2.	Ellis, Peter: 2 articles (09/2010 - 09/2010)
3.	Haughie, Scott: 2 articles (09/2010 - 09/2010)
4.	Lamb, Janice: 2 articles (09/2010 - 09/2010)
5.	Tamimi, Nihad A M: 2 articles (09/2010 - 09/2010)
6.	Kaplan, Steven A: 1 article (01/2012)
7.	Giuliano, Francois A: 1 article (09/2010)
8.	Mincik, Ivan: 1 article (09/2010)

Related Diseases

1.	Lower Urinary Tract Symptoms 01/01/2012 - "Re: A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia." 09/01/2010 - "A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia." 09/01/2010 - "A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder." 09/01/2010 - "To evaluate the efficacy and safety of the phosphodiesterase type 5 inhibitor, UK-369,003 modified release (MR), for the treatment of storage lower urinary tract symptoms (LUTS) in men with and without erectile dysfunction (ED). " 09/01/2010 - "To evaluate the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in men with and without erectile dysfunction (ED). "
2.	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/01/2012 - "Re: A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia." 09/01/2010 - "A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia." 09/01/2010 - "To evaluate the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in men with and without erectile dysfunction (ED). "
3.	Overactive Urinary Bladder (Overactive Bladder) 09/01/2010 - "In all, 310 men aged ≥ 18 years with a clinical diagnosis of overactive bladder (OAB; voiding frequency ≥ 8 times/24 h, urgency episode frequency once or more per 24 h and a mean voided volume of <300 mL) and maximum urinary flow rate of >5 mL/s in a voided volume of >150 mL were stratified into two groups (with or without ED) and randomized to one of five treatment groups (10, 25, 50 or 100 mg UK-369,003; or placebo once a day) for 12 weeks. " 09/01/2010 - "A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder."
4.	Erectile Dysfunction 09/01/2010 - "To evaluate the efficacy and safety of the phosphodiesterase type 5 inhibitor, UK-369,003 modified release (MR), for the treatment of storage lower urinary tract symptoms (LUTS) in men with and without erectile dysfunction (ED). " 09/01/2010 - "To evaluate the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in men with and without erectile dysfunction (ED). "
5.	Nocturia 09/01/2010 - "Overall, there were no clinically relevant treatment differences in voiding frequency, mean voided volume, urgency episode frequency, or nocturia frequency for any dose of UK-369,003 MR compared with placebo. "

Related Drugs and Biologics

1.	Phosphodiesterase 5 Inhibitors